Is IPSC or RLAY more undervalued in 2026?

CirclFi compares Century Therapeutics, Inc. (IPSC) and Relay Therapeutics, Inc. (RLAY) using 13 institutional-grade valuation models. IPSC has a Quality of Company score of 5.9/10 while RLAY scores 6.0/10.

Which is a better buy — IPSC or RLAY?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do IPSC and RLAY valuations compare?

IPSC at $2.38 and RLAY at $13.90 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

IPSC vs RLAY Valuation Comparison 2026 — Intrinsic Value Analysis

IPSC

Biological Products, (No Diagnostic Substances)

Century Therapeutics, Inc.

Quality

5.9

out of 10

Value Trap

SAFE

Price

$2.38

Last close

Models

12/13

Active

RLAY

Biological Products, (No Diagnostic Substances)

Relay Therapeutics, Inc.

Quality

6.0

out of 10

Value Trap

SAFE

Price

$13.90

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	IPSC Fair Value	IPSC Upside	RLAY Fair Value	RLAY Upside
Bayesian DCF	Intrinsic	$0.65	-72.8%	$5.06	-63.6%
Earnings Power Value	Intrinsic	$1.16	-49.5%	$7.19	-52.5%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for IPSC vs RLAY — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

IPSC vs RLAY — Which Stock Is More Undervalued?

RLAY scores higher with a 6.0/10 quality rating vs IPSC's 5.9/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Century Therapeutics, Inc. (IPSC) and Relay Therapeutics, Inc. (RLAY) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

IPSC currently trades at $2.38 with a QOC of 5.9/10, while RLAY trades at $13.90 with a QOC of 6.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).